UnitedHealth Rockets 11%, Humana Climbs 9% as Medicare Advantage Rate Decision Crushes Regulatory Fears

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock is up nearly 11% today, moving from $281.36 to $311 and change, as the managed care sector stages a powerful relief rally. Humana (NYSE:HUM) shares are right behind, climbing 9% from $182.65 to over $198. The catalyst: a better-than-expected CMS Medicare Advantage rate decision.

The Centers for Medicare & Medicaid Services finalized a 2.48% payment increase for 2027 Medicare Advantage plans, coming in above the high end of the 1% to 2% improvement versus the proposal that the market was expecting. That gap between fear and reality is fueling today’s move. For a sector that spent much of the past year pricing in regulatory disaster, this announcement reads like a reprieve.

The CMS decision also projects a net average increase of over $13 billion in additional Medicare Advantage payments to plans in 2027. That’s real money flowing back into a business model that needed a margin recovery runway.

UnitedHealth: Scale and Optum Make It the Biggest Beneficiary

UnitedHealth Group shares entered today already battered. The stock was down 14.11% year-to-date heading into this session. This reflected how severely investors had penalized the company for Medicare Advantage cost pressures, a cyberattack remediation bill of $799 million, and a full-year adjusted medical care ratio that reached 88.9%, up 340 basis points year over year.

Today’s CMS decision changes the calculus. UnitedHealth Group is well-positioned to benefit from this rate increase due to its scale and integrated Optum platform, despite facing near-term membership declines in pursuit of profitability. The company guided for 2026 revenue above $439 billion and adjusted EPS above $17.75, and a cleaner reimbursement environment gives those targets more credibility.

Bank of America responded by raising its price target on UNH stock to $337 from $315, maintaining a Neutral rating. The analyst consensus is more constructive, with 22 Buy ratings, 5 Hold ratings, and 2 Sell ratings, with a consensus price target of $357.81. Short squeeze dynamics may also be amplifying today’s move, as UnitedHealth Group had been among the hardest-hit managed care names over the past year before today’s relief rally.

Humana: Wells Fargo Upgrade Adds Fuel to the Fire

Humana’s situation coming into today was arguably more distressed as the stock was down 28.32% year-to-date. Star Ratings headwinds had been crushing Humana’s 2026 Medicare Advantage bonus payments, and the company’s 2026 adjusted EPS guidance of at least $9 represented a steep decline from $17.14 in fiscal year 2025.

Today’s CMS announcement provides a clearer path forward. Wells Fargo raised its price target on Humana stock to $227 from $206 (Equal Weight), while Bank of America raised its target to $210 from $196 (Neutral). The revised rates provide a clearer path for margin recovery for health plans, according to Wells Fargo’s note. Humana also guided for approximately 25% individual Medicare Advantage membership growth in 2026, which becomes a more attractive growth story if reimbursement rates hold.

Humana’s Q4 2025 insurance segment benefit ratio came in at 93.1%, a level that leaves little room for error. The CMS rate increase doesn’t solve every challenge overnight, but it removes a significant overhang that had been weighing on the stock for months.

Sector-Wide Relief: Peers Rally on the Same Catalyst

Today’s relief rally extends well beyond UNH and HUM. An example is Elevance Health (NYSE:ELV) stock, which is up 3% to 4% today, with Bank of America raising its price target to $405 from $385 (Neutral). For a broader look at which managed care names stand to benefit most, see our coverage of 5 Stocks That Should Benefit from the 2026 Medicare Advantage Rate Decision.

That said, today’s celebration deserves a measured read. The CMS decision addresses Medicare Advantage reimbursement, but uncertainty in Medicaid and the Exchanges remains real. UnitedHealth Group is also expecting membership to contract by 2.3 to 2.8 million in 2026 from strategic right-sizing. Additionally, Humana still faces a challenging path to its 2028 earnings targets. One favorable rate decision doesn’t erase those structural headwinds.

Retail sentiment on Reddit’s r/stocks captured the mood well, with one user asking, “Any of you guys also built positions on UNH during this year-long downturn? Things may get better from here!” The road to recovery remains long for both companies, with structural headwinds still in place. Watch for whether UnitedHealth Group’s Q1 earnings report on April 21 confirms or disproves that the margin picture is actually turning.